UCB SA UCBJY
162.12 USD -3.15 (-1.91%)
Nov 11, 2026, 2:46 PM EST
160.56 Day range 162.12
110.55 52-week range 168.76
- YTD
- +16.00%
- 1 year
- +22.77%
- Market cap
- 61.72B
- EPS (ttm)
- 6.60
- P/E ratio
- 24.56
- YTD return
- +16.00%
- 1-year return
- +22.77%
- Volume
- 549
- Avg volume
- 44.60K
- Open
- 160.95
- Previous close
- 165.27
- Day's range
- 160.56 – 162.12
- 52-week range
- 110.55 – 168.76
- Earnings date
- Feb 25, 2027
5D +5.08 (+3.24%)
Next earnings
Feb 25, 2027
Expected Feb 25, 2027. Consensus EPS estimate 3.01.
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 25, 2027 | Dec 30, 2026 | 3.01 | — | — | — |
| Jul 30, 2026 | Jun 30, 2026 | 2.91 | 3.93 | +1.02 | +35.05% |
| Feb 26, 2026 | Dec 31, 2025 | 2.91 | 3.79 | +0.88 | +30.24% |
| Jul 31, 2025 | Jun 30, 2025 | 1.93 | 1.44 | -0.49 | -25.39% |
| Feb 27, 2025 | Dec 31, 2024 | 1.35 | 4.56 | +3.21 | +237.78% |
| Jul 25, 2024 | Jun 30, 2024 | 0.953 | 1.15 | +0.20 | +20.67% |
News
What's Going On with MoonLake Immunotherapeutics Stock on Thursday? 
Medicare Targets 15 High-Profile Drugs In Third Price Negotiation Cycle 
Johnson & Johnson Touts Encouraging Results For Experimental Lupus Treatment 
J&J Halts Alzheimer's Trial After Drug Fails To Slow Clinical Decline 
Benzinga's Top Ratings Upgrades, Downgrades For July 9, 2021
Your note
Sign in to keep a note on UCBJY — it syncs with the Stock Master app.